Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 711,463
  • Shares Outstanding, K 188,717
  • Annual Sales, $ 18,140 K
  • Annual Income, $ -72,850 K
  • 60-Month Beta 1.91
  • Price/Sales 38.82
  • Price/Cash Flow N/A
  • Price/Book 5.92
Trade ABUS with:

Options Overview Details

View History
  • Implied Volatility 57.37% ( +0.75%)
  • Historical Volatility 45.87%
  • IV Percentile 32%
  • IV Rank 9.58%
  • IV High 443.77% on 08/05/24
  • IV Low 16.46% on 05/21/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 326
  • Volume Avg (30-Day) 335
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 38,119
  • Open Int (30-Day) 40,119

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.11
  • Prior Year -0.12
  • Growth Rate Est. (year over year) +25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.65 +3.01%
on 10/01/24
4.61 -18.44%
on 09/11/24
-0.73 (-16.26%)
since 09/09/24
3-Month
3.30 +13.94%
on 08/05/24
4.72 -20.42%
on 09/09/24
+0.36 (+10.59%)
since 07/09/24
52-Week
1.69 +122.49%
on 10/24/23
4.72 -20.42%
on 09/09/24
+1.90 (+102.15%)
since 10/09/23

Most Recent Stories

More News
Arbutus: Q2 Earnings Snapshot

Arbutus: Q2 Earnings Snapshot

ABUS : 3.76 (-0.27%)
3 Outperforming Stocks to Buy With $500 Right Now

With a budget of around $500, investors can scoop up these three standout stock picks, which have outperformed the broader market in the past year.

$SPX : 5,792.04 (+0.71%)
APPF : 225.16 (-0.43%)
PI : 228.62 (+2.25%)
ABUS : 3.76 (-0.27%)
Arbutus: Q1 Earnings Snapshot

Arbutus: Q1 Earnings Snapshot

ABUS : 3.76 (-0.27%)
Arbutus: Q3 Earnings Snapshot

Arbutus: Q3 Earnings Snapshot

ABUS : 3.76 (-0.27%)
3 Stocks to Buy For the COVID Resurgence

The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting

MRNA : 58.86 (+0.80%)
NVAX : 12.68 (-2.76%)
PFE : 30.19 (+3.46%)
ALNY : 270.90 (-0.11%)
ABUS : 3.76 (-0.27%)
BNTX : 117.47 (-2.35%)
CVAC : 2.91 (+0.69%)
LGF-A : N/A (N/A)
Arbutus: Q2 Earnings Snapshot

Arbutus: Q2 Earnings Snapshot

ABUS : 3.76 (-0.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...

ABUS : 3.76 (-0.27%)
Arbutus: Q1 Earnings Snapshot

Arbutus: Q1 Earnings Snapshot

ABUS : 3.76 (-0.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...

ABUS : 3.76 (-0.27%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arbutus Biopharma Corporation - ABUS

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arbutus Biopharma Corporation ("Arbutus" or the "Company") (NASDAQ: ABUS). Such...

ABUS : 3.76 (-0.27%)

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 3.87
2nd Resistance Point 3.83
1st Resistance Point 3.79
Last Price 3.76
1st Support Level 3.71
2nd Support Level 3.67
3rd Support Level 3.63

See More

52-Week High 4.72
Last Price 3.76
Fibonacci 61.8% 3.57
Fibonacci 50% 3.21
Fibonacci 38.2% 2.85
52-Week Low 1.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar